Search clinical trials for: BI-6727

Total 1256 results

Universidade Federal do Rio Grande do Norte

Completed

Non Invasive Ventilation on Peripheral Muscle Function and Aerobic Performance (NIV)

Chronic Obstructive Pulmonary Disease

Brazil
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 456906 in Patients With Obesity

Obesity

Germany
Kyungpook National University Chilgok Hospital
Kyungpook National University Hospital

Completed

Impact of the Type of Reconstruction Methods on Diabetes Following Laparoscopic Distal Gastrectomy in Patients With Gastric Cancer and Type 2 Diabetes

Diabetes Mellitus, Type 2 | Stomach Neoplasms

Korea, Republic of
Boehringer Ingelheim

Completed

Olmutinib (BI 1482694) ADME Study

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety of Single Rising Doses and Relative Bioavailability of BI 691751

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses of BI 44370 BS Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Withdrawn

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667

Healthy
Boehringer Ingelheim

Completed

Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.

Healthy

Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
Boehringer Ingelheim

Completed

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Japan
Palobiofarma SL

Completed

"First-in-human" Study To Assess the Safety and Tolerability of PBF-677 in Healthy Volunteers

Glaucoma
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD

Pulmonary Disease, Chronic Obstructive

Japan
University of Colorado, Denver
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial

Asthma in Children

United States
University of Manitoba
Canadian IBD Research Consortium (CIRC)

Not yet recruiting

Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease.

Crohn Disease | Ulcerative Colitis
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine

Depressive Disorder, Major

United States
Erasmus Medical Center

Enrolling by invitation

Validation of SMS Protocol for HCC Screening in High-risk Patients

Hepatocellular Carcinoma

Netherlands
Boehringer Ingelheim

Completed

Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis

Psoriasis

Taiwan, Malaysia, France, Japan, Korea, Republic of, Tunisia
Boehringer Ingelheim

Completed

A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body

Healthy

China
Boehringer Ingelheim

Completed

An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis

Lupus Nephritis

United Kingdom, Thailand, Germany, Japan, United States, Australia, Korea, Republic of, Hong Kong, Poland, Greece, Mexico, Czechia, Canada, Malaysia, Philippines, Portugal
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2

Healthy

Japan
Biointegrator LLC

Terminated

Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab

Metastatic Breast Cancer

Russian Federation
Boehringer Ingelheim

Completed

Safety Tolerability and Pharmacokinetic of BI 411034

Healthy

Germany
Boehringer Ingelheim

Completed

Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Terminated

To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).

Pain | Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men and Women Tests How the Body Takes up BI 409306

Healthy

Germany
Myrexis Inc.

Completed

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

Metastatic Melanoma

United States
Boehringer Ingelheim

Not yet recruiting

A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems

Healthy | Renal Impairment
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated

Healthy

Germany
Boehringer Ingelheim

Completed

To Assess Safety, Tolerability and Pharmacokinetics of BI 730357 in Healthy Male Volunteers

Healthy Volunteers

Germany
Boehringer Ingelheim

Completed

Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers

Healthy

Japan, Korea, Republic of
Boehringer Ingelheim

Terminated

Evaluation of Safety and Tolerability of Single Rising Doses of BI 473494 in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Terminated

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

Cystic Fibrosis

United States, Spain, Belgium, Germany, Canada, United Kingdom, Sweden, France
Boehringer Ingelheim

Completed

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms

Healthy

Netherlands
Manchester Metropolitan University
Manchester University NHS Foundation Trust

Unknown

Non Invasive Ventilation for Acute Exacerbations in Adult CF (NIVinCF)

Respiratory Failure | Cystic Fibrosis

United Kingdom
Boehringer Ingelheim

Completed

First in Man Trial of BI 113608

Healthy

Germany
Boehringer Ingelheim

Terminated

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

Healthy

United States
US Department of Veterans Affairs

Completed

Veterans Intensive Personalized Treatment in Heart Failure (VIP)

Heart Failure

United States
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of BI 11634 Oral Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Powder in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Withdrawn

Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.

HIV Infections | Healthy
Brown University
National Institute on Aging (NIA); Meals on Wheels America

Completed

Home-delivered Meals for Persons With Dementia: Which Model Delays Nursing Home Placement?

Dementia

United States
Boehringer Ingelheim

Completed

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems

Renal Insufficiency

Germany
Boehringer Ingelheim

Completed

A Study in Healthy People to Test How BI 425809 is Taken up in the Body When Taken With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

Dermatitis, Atopic

United States, Japan, Canada
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Diabetes Mellitus, Type 2

United States, Australia, Canada, Germany, Spain, Taiwan, Hungary, Poland, Korea, Republic of, Austria, New Zealand, United Kingdom, Czechia, Puerto Rico
Cartiheal (2009) Ltd

Completed

Evaluation of the Agili-C Biphasic Implant in the Knee Joint

Cartilage Diseases | Osteochondritis Dissecans

Czechia, Italy, Croatia, Hungary, Poland, Romania, Serbia, Slovenia
University of California, San Diego

Completed

Right Ventricular Hemodynamics Using Cardiac MRI in Patients COPD and OSA

Chronic Obstructive Pulmonary Disease | Obstructive Sleep Apnea | Overlap Syndrome

United States

3

Subscribe